Table 1.
Clinical and biological characteristics of patients with chronic lymphocytic leukemia (CLL).
| Parameter | |
|---|---|
| Age (median) | 70.5 years |
| Sex m/f | 27 (49.1%)/28 (50.9%) |
| Rai stage 0/I | 38 (69.1%)/17 (30.9%) |
| ECOG 0/1 | 53 (96.4%)/2 (3.6%) |
| IGHV status | Mutated: 46 (83.6%) Unmutated: 7 (12.7%) Indeterminate: 2 (3.6%) |
| CD38 pos/neg | 8 (14.5%)/47 (85.5%) |
| ZAP-70 pos/neg | 4 (7.4%)/50 (92.6%) |
| FISH caryotype | No alteration: 14 (25.5%) Del(13q): 33 (60%) Del(17p): 4 (7.3%) Trisomy 12: 2 (3.6%) Del(11q): 1 (1.8%) Complex Karyotype: 0 (0%) |
| SCNA (detected by WES) | No alteration: 13 (23.6%) Del(13q): 35 (63.3%) Trisomy 12: 3 (5.4%) Del(17p): 2 (3.6%) Del(11q): 1 (1.8%) Others (G2p16 (1); L18p (1); L6q15 (2); G2p26 (1); G5q34 (1); G8q24 (1); L3p21.31 (1); G3q26 (1); L15p26 (1); L20p (1) |
| Driver mutations (pos/neg) | 24 (43.8%)/31 (56.4%) |
| Type of mutation | Adverse mutation: 11 (20%) Protective mutation: 5 (9.1%) Other mutations: 8 (14.5%) |
| Number of mutations | 0: 31 (56.4%) 1: 15 (27.3%) 2: 6 (10.9%) 3: 2 (3.6%) 7: 1 (1.8%) |
| Genetic and SCNA groups | Adverse: 12 (21.8%) Protective: 31 (56.3%) Neither: 12 (21.8%) |
m: Male; f: Female; pos: Positive; neg: Negative; SCNAs: Somatic copy number alterations; WES: Whole exome sequencing; IGHV, immunoglobulin heavy chain genes; FISH, fluorescence-in situ hybridization; ECOG, Eastern Cooperative Oncology Group; CD38, cluster of differentiation 38; ZAP-70, zeta-chain-associated protein kinase 70. Unfavorable mutations: NOTCH1, TP53, ATM, SF3B1, BIRC3 and ZNF292. Favorable mutations: CHD2 and KHKL6.